New therapeutics in rheumatoid arthritis.
Rheumatoid arthritis (RA) is a systemic disorder characterized predominately by a chronic inflammatory polyarthritis, with frequent progression to joint destruction and disability. Radiographic joint damage develops in as many as 75% of patients within the first 2 years of disease. For this reason, current RA treatment approaches have focused on early intensive therapy with multiple disease-modifying antirheumatic drugs. The approval of new drugs for this indication has expanded the number of therapeutic options that can potentially allow for tight control of the inflammatory process.
Savage
Christine
C
Duke University Medical Center, Durham, NC 27710, USA.
St Clair
E William
EW
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*
D018501:Antirheumatic Agents; D050071:Bone Density Conservation Agents; D016207:Cytokines; D007166:Immunosuppressive Agents